Late-breaking Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA® (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
TREMFYA® (guselkumab) showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 study1,2 Guselkumab demonstrated more than 2 times greater reduction…
